Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Leases (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Operating Leases for 4 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 1.04% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 1.04% increase, with the full-year FY2025 number at $2.6 million, up 1.04% from a year prior.
  • Operating Leases was $2.6 million for Q4 2025 at Day One Biopharmaceuticals, down from $2.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.9 million in Q1 2025 to a low of $77000.0 in Q3 2023.
  • A 4-year average of $1.5 million and a median of $1.6 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: plummeted 85.02% in 2023, then skyrocketed 3196.1% in 2024.
  • Day One Biopharmaceuticals' Operating Leases stood at $408000.0 in 2022, then crashed by 81.13% to $77000.0 in 2023, then skyrocketed by 3266.23% to $2.6 million in 2024, then rose by 1.04% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Operating Leases are $2.6 million (Q4 2025), $2.7 million (Q3 2025), and $2.8 million (Q2 2025).